Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Cancer Institute at Oregon Health and Science University
mi
from
Portland, OR
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Cancer Institute at Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Legacy Meridian Park Hospital
mi
from
Tualatin, OR
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Legacy Meridian Park Hospital
mi
from
Tualatin, OR
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Danville Regional Medical Center
mi
from
Danville, VA
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Danville Regional Medical Center
mi
from
Danville, VA
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Auburn Regional Center for Cancer Care
mi
from
Auburn, WA
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Auburn Regional Center for Cancer Care
mi
from
Auburn, WA
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
St. Joseph Hospital Community Cancer Center
mi
from
Bellingham, WA
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
St. Joseph Hospital Community Cancer Center
mi
from
Bellingham, WA
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Olympic Hematology and Oncology
mi
from
Bremerton, WA
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Olympic Hematology and Oncology
mi
from
Bremerton, WA
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Regional Cancer Center at Providence Hospital
mi
from
Centralia, WA
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Regional Cancer Center at Providence Hospital
mi
from
Centralia, WA
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
St. Francis Hospital
mi
from
Federal Way, WA
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
St. Francis Hospital
mi
from
Federal Way, WA
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Providence St. Peter Hospital Regional Cancer Center
mi
from
Olympia, WA
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Providence St. Peter Hospital Regional Cancer Center
mi
from
Olympia, WA
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Capital Medical Center
mi
from
Olympia, WA
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Capital Medical Center
mi
from
Olympia, WA
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Good Samaritan Cancer Center
mi
from
Puyallup, WA
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Good Samaritan Cancer Center
mi
from
Puyallup, WA
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Group Health Capitol Hill Campus
mi
from
Seattle, WA
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Group Health Capitol Hill Campus
mi
from
Seattle, WA
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Harborview Medical Center
mi
from
Seattle, WA
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Harborview Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
mi
from
Seattle, WA
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
mi
from
Seattle, WA
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
University Cancer Center at University of Washington Medical Center
mi
from
Seattle, WA
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
University Cancer Center at University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Cancer Care Northwest - Spokane South
mi
from
Spokane, WA
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Cancer Care Northwest - Spokane South
mi
from
Spokane, WA
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Allenmore Hospital
mi
from
Tacoma, WA
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Allenmore Hospital
mi
from
Tacoma, WA
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
CCOP - Northwest
mi
from
Tacoma, WA
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
CCOP - Northwest
mi
from
Tacoma, WA
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
St. Joseph Medical Center at Franciscan Health System
mi
from
Tacoma, WA
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
St. Joseph Medical Center at Franciscan Health System
mi
from
Tacoma, WA
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
St. Clare Hospital
mi
from
Tacoma, WA
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
St. Clare Hospital
mi
from
Tacoma, WA
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Southwest Washington Medical Center Cancer Center
mi
from
Vancouver, WA
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Southwest Washington Medical Center Cancer Center
mi
from
Vancouver, WA
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Central Washington Hospital
mi
from
Wenatchee, WA
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Central Washington Hospital
mi
from
Wenatchee, WA
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Wenatchee Valley Clinic
mi
from
Wenatchee, WA
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Wenatchee Valley Clinic
mi
from
Wenatchee, WA
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Community Comprehensive Cancer Center at Camden-Clark Memorial Hospital
mi
from
Parkersburg, WV
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Community Comprehensive Cancer Center at Camden-Clark Memorial Hospital
mi
from
Parkersburg, WV
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Welch Cancer Center
mi
from
Sheridan, WY
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Welch Cancer Center
mi
from
Sheridan, WY
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Legacy Mount Hood Medical Center
mi
from
Gresham, OR
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Legacy Mount Hood Medical Center
mi
from
Gresham, OR
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Skagit Valley Hospital Cancer Care Center
mi
from
Mount Vernon, WA
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Skagit Valley Hospital Cancer Care Center
mi
from
Mount Vernon, WA
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
North Puget Oncology at United General Hospital
mi
from
Sedro-Woolley, WA
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
North Puget Oncology at United General Hospital
mi
from
Sedro-Woolley, WA
Click here to add this to my saved trials
Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
Status: Enrolling
Updated:  10/4/2017
Memorial Hospital Central
mi
from
Colorado Springs, CO
Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
Status: Enrolling
Updated: 10/4/2017
Memorial Hospital Central
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
Status: Enrolling
Updated:  10/4/2017
Memorial Hospital North
mi
from
Colorado Springs, CO
Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
Status: Enrolling
Updated: 10/4/2017
Memorial Hospital North
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
Status: Enrolling
Updated:  10/4/2017
Denver Health Medical Center, Medical ICU
mi
from
Denver, CO
Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
Status: Enrolling
Updated: 10/4/2017
Denver Health Medical Center, Medical ICU
mi
from
Denver, CO
Click here to add this to my saved trials
Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
Status: Enrolling
Updated:  10/4/2017
Porter Adventist Hospital
mi
from
Denver, CO
Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
Status: Enrolling
Updated: 10/4/2017
Porter Adventist Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
Status: Enrolling
Updated:  10/4/2017
St. Anthony Hospital
mi
from
Lakewood, CO
Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
Status: Enrolling
Updated: 10/4/2017
St. Anthony Hospital
mi
from
Lakewood, CO
Click here to add this to my saved trials
Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
Status: Enrolling
Updated:  10/4/2017
Louisiana State University
mi
from
New Orleans, LA
Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
Status: Enrolling
Updated: 10/4/2017
Louisiana State University
mi
from
New Orleans, LA
Click here to add this to my saved trials
Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
Status: Enrolling
Updated:  10/4/2017
Ben Taub Hospital
mi
from
Houston, TX
Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
Status: Enrolling
Updated: 10/4/2017
Ben Taub Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Losartan to Reverse Sickle Nephropathy
A Phase II Trial of Losartan to Reverse Sickle Nephropathy
Status: Enrolling
Updated:  10/4/2017
University of Illinois at Chicago
mi
from
Chicago, IL
Losartan to Reverse Sickle Nephropathy
A Phase II Trial of Losartan to Reverse Sickle Nephropathy
Status: Enrolling
Updated: 10/4/2017
University of Illinois at Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Losartan to Reverse Sickle Nephropathy
A Phase II Trial of Losartan to Reverse Sickle Nephropathy
Status: Enrolling
Updated:  10/4/2017
University of Louisville
mi
from
Louisville, KY
Losartan to Reverse Sickle Nephropathy
A Phase II Trial of Losartan to Reverse Sickle Nephropathy
Status: Enrolling
Updated: 10/4/2017
University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
Losartan to Reverse Sickle Nephropathy
A Phase II Trial of Losartan to Reverse Sickle Nephropathy
Status: Enrolling
Updated:  10/4/2017
NHLBI
mi
from
Bethesda, MD
Losartan to Reverse Sickle Nephropathy
A Phase II Trial of Losartan to Reverse Sickle Nephropathy
Status: Enrolling
Updated: 10/4/2017
NHLBI
mi
from
Bethesda, MD
Click here to add this to my saved trials
Losartan to Reverse Sickle Nephropathy
A Phase II Trial of Losartan to Reverse Sickle Nephropathy
Status: Enrolling
Updated:  10/4/2017
Akron Children's Hospital
mi
from
Akron, OH
Losartan to Reverse Sickle Nephropathy
A Phase II Trial of Losartan to Reverse Sickle Nephropathy
Status: Enrolling
Updated: 10/4/2017
Akron Children's Hospital
mi
from
Akron, OH
Click here to add this to my saved trials
Losartan to Reverse Sickle Nephropathy
A Phase II Trial of Losartan to Reverse Sickle Nephropathy
Status: Enrolling
Updated:  10/4/2017
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Losartan to Reverse Sickle Nephropathy
A Phase II Trial of Losartan to Reverse Sickle Nephropathy
Status: Enrolling
Updated: 10/4/2017
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Losartan to Reverse Sickle Nephropathy
A Phase II Trial of Losartan to Reverse Sickle Nephropathy
Status: Enrolling
Updated:  10/4/2017
University of Cincinnati
mi
from
Cincinnati, OH
Losartan to Reverse Sickle Nephropathy
A Phase II Trial of Losartan to Reverse Sickle Nephropathy
Status: Enrolling
Updated: 10/4/2017
University of Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Losartan to Reverse Sickle Nephropathy
A Phase II Trial of Losartan to Reverse Sickle Nephropathy
Status: Enrolling
Updated:  10/4/2017
Nationwide Children's Hospital
mi
from
Columbus, OH
Losartan to Reverse Sickle Nephropathy
A Phase II Trial of Losartan to Reverse Sickle Nephropathy
Status: Enrolling
Updated: 10/4/2017
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Losartan to Reverse Sickle Nephropathy
A Phase II Trial of Losartan to Reverse Sickle Nephropathy
Status: Enrolling
Updated:  10/4/2017
Texas Children's Hospital
mi
from
Houston, TX
Losartan to Reverse Sickle Nephropathy
A Phase II Trial of Losartan to Reverse Sickle Nephropathy
Status: Enrolling
Updated: 10/4/2017
Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Losartan to Reverse Sickle Nephropathy
A Phase II Trial of Losartan to Reverse Sickle Nephropathy
Status: Enrolling
Updated:  10/4/2017
University of Texas Southwestern
mi
from
Dallas, TX
Losartan to Reverse Sickle Nephropathy
A Phase II Trial of Losartan to Reverse Sickle Nephropathy
Status: Enrolling
Updated: 10/4/2017
University of Texas Southwestern
mi
from
Dallas, TX
Click here to add this to my saved trials
Safe@Home: A Self-Management Program for Individuals With TBI and Their Families
Safe@Home: A Self-Management Program for Individuals With Traumatic Brain Injury and Their Families
Status: Enrolling
Updated:  10/4/2017
Shepherd Center
mi
from
Atlanta, GA
Safe@Home: A Self-Management Program for Individuals With TBI and Their Families
Safe@Home: A Self-Management Program for Individuals With Traumatic Brain Injury and Their Families
Status: Enrolling
Updated: 10/4/2017
Shepherd Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
Brain Infusion of Muscimol to Treat Epilepsy
Trial of Intracerebral Infusion in Patients With Medically Intractable Epilepsy
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Brain Infusion of Muscimol to Treat Epilepsy
Trial of Intracerebral Infusion in Patients With Medically Intractable Epilepsy
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Brain Anatomy in Dystonia
In Vivo Mapping Of Structural and Biochemical Abnormalities In Patients With Primary Focal Dystonia
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Brain Anatomy in Dystonia
In Vivo Mapping Of Structural and Biochemical Abnormalities In Patients With Primary Focal Dystonia
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Clinical and Immunological Investigations of Subtypes of Autism
Clinical and Immunological Investigations of Subtypes of Autism
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Clinical and Immunological Investigations of Subtypes of Autism
Clinical and Immunological Investigations of Subtypes of Autism
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Collection of Blood Samples for DNA in Motor Neuron Disease
Collection of Blood Samples for DNA Analysis in Motor Neuron Diseases
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Collection of Blood Samples for DNA in Motor Neuron Disease
Collection of Blood Samples for DNA Analysis in Motor Neuron Diseases
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials